Passage Bio, Inc. (PASG) Prices 12M Share IPO at $18/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Passage Bio Announces Pricing of Initial Public Offering
February 27, 2020 7:24 PM ESTPHILADELPHIA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced the pricing of its initial public offering of 12,000,000 shares of common stock at a public offering price of $18.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Passage Bio, are expected to be $216.0 million. All of the shares are being offered by Passage Bio. The offering is expected to close on March 3, 2020, subject to... More



